PMV Pharmaceuticals Inc

NASDAQ:PMVPUnited States

PMV Pharmaceuticals, Inc. is a precision oncology company, which is engaged in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a tumor suppressor protein, guardian of the genome, and normal or wild type, p53 has the ability to eliminate cancer cells. The Company’s lead product candidate, PC14586 is designed to bind to the mutation site and structurally correct the misfolded p53 protein, while sparing wild-type p53PC14586 has shown selective on-target activity, which primarily functions in cells with the p53 Y220C mutation and exhibited robust anti-tumor activity evidenced by potent tumor growth inhibition (TGI), and tumor regression as a single agent. The Company has initiated a Phase I/II clinical trial for PC14586. In addition, it is also granted food and drug administration (FDA) Fast Track designation of PC14586 for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation.

Contact Information

Headquarters

One Research WayPRINCETON, NJ, United States 08540

Phone

609-642-6664

Fax

302-636-5454

Executives

Independent Chairman of the Board

Richard Heyman

Co-Founder, Director

David Mack

Chief Financial Officer, Chief Operating Officer

Winston Kung

Chief Medical Officer

Leila Alland

Chief Regulatory, Quality Assurance Officer

Deepika Jalota